oleanolic acid has been researched along with Weight Loss in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kalantar-Zadeh, K; Tayek, JA | 1 |
| Akizawa, T; Audhya, P; Bakris, GL; Chertow, GM; Chin, M; Christ-Schmidt, H; de Zeeuw, D; Goldsberry, A; Houser, M; Krauth, M; Lambers Heerspink, HJ; McMurray, JJ; Meyer, CJ; Parving, HH; Remuzzi, G; Toto, RD; Vaziri, ND; Wanner, C; Wittes, J; Wrolstad, D | 1 |
1 trial(s) available for oleanolic acid and Weight Loss
| Article | Year |
|---|---|
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; NF-E2-Related Factor 2; Oleanolic Acid; Renal Insufficiency, Chronic; Treatment Failure; Weight Loss | 2013 |
1 other study(ies) available for oleanolic acid and Weight Loss
| Article | Year |
|---|---|
The extinguished BEACON of bardoxolone: not a Monday morning quarterback story.
Topics: Anti-Inflammatory Agents; Diabetic Nephropathies; Early Termination of Clinical Trials; Humans; Oleanolic Acid; Proteinuria; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Spasm; Weight Loss | 2013 |